Beone Medicines Rises 1.34% With H1 Revenue Reaching 22.2 Billion Yuan as Global Expansion Accelerates

Deep News08-18 18:11

Beone Medicines closed at 293.78 yuan today, up 1.34%, with a trading volume of 1.736 billion yuan, a turnover rate of 5.147%, and a volume ratio of 0.71. The company's total market capitalization stands at approximately 305.175 billion yuan, with a TTM price-to-earnings ratio of roughly 143.263 times.

On the news front, the company disclosed its 2026 half-year key financial data on August 6 and voluntarily announced adjustments to its operating performance forecast. The first half continued to demonstrate robust growth momentum, with the global expansion of its core products remaining the market's primary focus. Today's share price movement aligns with expectations tied to both sector performance and the company's fundamentals.

The company is a global leader in innovative oncology treatments, with core products including Brukinsa® (zanubrutinib), TEVIMBRA® (tislelizumab), and pamiparib, among others. Its pipeline covers both hematologic malignancies and solid tumors, supported by a commercialization network that spans the globe.

From a fundamental perspective, the company's total operating revenue for the first half reached 22.220 billion yuan, up 26.8% year-over-year. Product revenue contributed 21.797 billion yuan, marking a 25.6% increase. Notably, global sales of Brukinsa® reached 16.127 billion yuan, up 28.7%, while TEVIMBRA® generated 2.984 billion yuan, up 12.9%. Net profit attributable to shareholders surged 627.1% to 3.271 billion yuan, underscoring that global expansion has driven significant improvements in profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123461158?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 18:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123461158","market":"other","top_or_hot":-1,"title":"Beone Medicines Rises 1.34% With H1 Revenue Reaching 22.2 Billion Yuan as Global Expansion Accelerates","media":"Deep News","content":"<p><b>Beone Medicines</b> closed at 293.78 yuan today, up 1.34%, with a trading volume of 1.736 billion yuan, a turnover rate of 5.147%, and a volume ratio of 0.71. The company's total market capitalization stands at approximately 305.175 billion yuan, with a TTM price-to-earnings ratio of roughly 143.263 times.<br><br>On the news front, the company disclosed its 2026 half-year key financial data on August 6 and voluntarily announced adjustments to its operating performance forecast. The first half continued to demonstrate robust growth momentum, with the global expansion of its core products remaining the market's primary focus. Today's share price movement aligns with expectations tied to both sector performance and the company's fundamentals.<br><br>The company is a global leader in innovative oncology treatments, with core products including Brukinsa® (zanubrutinib), TEVIMBRA® (tislelizumab), and pamiparib, among others. Its pipeline covers both hematologic malignancies and solid tumors, supported by a commercialization network that spans the globe.<br><br>From a fundamental perspective, the company's total operating revenue for the first half reached 22.220 billion yuan, up 26.8% year-over-year. Product revenue contributed 21.797 billion yuan, marking a 25.6% increase. Notably, global sales of Brukinsa® reached 16.127 billion yuan, up 28.7%, while TEVIMBRA® generated 2.984 billion yuan, up 12.9%. Net profit attributable to shareholders surged 627.1% to 3.271 billion yuan, underscoring that global expansion has driven significant improvements in profitability.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beone Medicines Rises 1.34% With H1 Revenue Reaching 22.2 Billion Yuan as Global Expansion Accelerates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeone Medicines Rises 1.34% With H1 Revenue Reaching 22.2 Billion Yuan as Global Expansion Accelerates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-18 18:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Beone Medicines</b> closed at 293.78 yuan today, up 1.34%, with a trading volume of 1.736 billion yuan, a turnover rate of 5.147%, and a volume ratio of 0.71. The company's total market capitalization stands at approximately 305.175 billion yuan, with a TTM price-to-earnings ratio of roughly 143.263 times.<br><br>On the news front, the company disclosed its 2026 half-year key financial data on August 6 and voluntarily announced adjustments to its operating performance forecast. The first half continued to demonstrate robust growth momentum, with the global expansion of its core products remaining the market's primary focus. Today's share price movement aligns with expectations tied to both sector performance and the company's fundamentals.<br><br>The company is a global leader in innovative oncology treatments, with core products including Brukinsa® (zanubrutinib), TEVIMBRA® (tislelizumab), and pamiparib, among others. Its pipeline covers both hematologic malignancies and solid tumors, supported by a commercialization network that spans the globe.<br><br>From a fundamental perspective, the company's total operating revenue for the first half reached 22.220 billion yuan, up 26.8% year-over-year. Product revenue contributed 21.797 billion yuan, marking a 25.6% increase. Notably, global sales of Brukinsa® reached 16.127 billion yuan, up 28.7%, while TEVIMBRA® generated 2.984 billion yuan, up 12.9%. Net profit attributable to shareholders surged 627.1% to 3.271 billion yuan, underscoring that global expansion has driven significant improvements in profitability.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1770034418.SGD","symbol_name":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","start_time":0,"source_url":"","article_id":"1123461158","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123461158","pubTimestamp":1787047890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Beone Medicines closed at 293.78 yuan today, up 1.34%, with a trading volume of 1.736 billion yuan, a turnover rate of 5.147%, and a volume ratio of 0.71. The company's total market capitalization...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","BK4588":"碎股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1500":"做空集合股","06160":"百济神州","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1588":"回港中概股","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK1161":"生物科技","LU0828237510.HKD":"SCHRODER ISF BIC (BRAZ IN CH)\"A\" (HKD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0228659784.USD":"施罗德金砖四国基金","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","BK1583":"高瓴概念","ONC":"百济神州","BK0239":"医药制造","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC"},"translate_title":"随着全球扩张加速，Beone Medicines上半年营收达到222亿元，上半年上半年上涨1.34%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"06160":1,"KURE":1,"ONC":1},"content_text":"Beone Medicines closed at 293.78 yuan today, up 1.34%, with a trading volume of 1.736 billion yuan, a turnover rate of 5.147%, and a volume ratio of 0.71. The company's total market capitalization stands at approximately 305.175 billion yuan, with a TTM price-to-earnings ratio of roughly 143.263 times.On the news front, the company disclosed its 2026 half-year key financial data on August 6 and voluntarily announced adjustments to its operating performance forecast. The first half continued to demonstrate robust growth momentum, with the global expansion of its core products remaining the market's primary focus. Today's share price movement aligns with expectations tied to both sector performance and the company's fundamentals.The company is a global leader in innovative oncology treatments, with core products including Brukinsa® (zanubrutinib), TEVIMBRA® (tislelizumab), and pamiparib, among others. Its pipeline covers both hematologic malignancies and solid tumors, supported by a commercialization network that spans the globe.From a fundamental perspective, the company's total operating revenue for the first half reached 22.220 billion yuan, up 26.8% year-over-year. Product revenue contributed 21.797 billion yuan, marking a 25.6% increase. Notably, global sales of Brukinsa® reached 16.127 billion yuan, up 28.7%, while TEVIMBRA® generated 2.984 billion yuan, up 12.9%. Net profit attributable to shareholders surged 627.1% to 3.271 billion yuan, underscoring that global expansion has driven significant improvements in profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123461158","isCrawlerRequest":true}